Variable | Overall survival | ||
---|---|---|---|
HR | 95% CI | p | |
Model A | |||
 Primary tumor (T) (III/IV vs I/II) | 2.056 | 1.335–3.166 | 0.001 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.750 | 1.152–2.660 | 0.009 |
 Distant metastasis (M) (Yes vs No) | 1.146 | 0.599–2.192 | 0.680 |
 TNM Stage (III/IV vs I/II) | 1.100 | 0.632–1.915 | 0.735 |
 EGFR (High vs Low) | 1.450 | 1.063–1.978 | 0.019 |
Model B | |||
 Primary tumor (T) (III/IV vs I/II) | 1.991 | 1.286–3.084 | 0.002 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.642 | 1.067–2.526 | 0.024 |
 Distant metastasis (M) (Yes vs No) | 1.106 | 0.577–2.119 | 0.761 |
 TNM Stage (III/IV vs I/II) | 1.149 | 0.650–2.032 | 0.632 |
 HER4 (High vs Low) | 1.198 | 0.875–1.641 | 0.259 |
Model C | |||
 Primary tumor (T) (III/IV vs I/II) | 1.931 | 1.243–3.002 | 0.003 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.594 | 1.026–2.446 | 0.038 |
 Distant metastasis (M) (Yes vs No) | 1.159 | 0.604–2.223 | 0.657 |
 TNM Stage (III/IV vs I/II) | 1.224 | 0.686–2.182 | 0.494 |
 EphA3 (High vs Low) | 1.372 | 1.014–1.855 | 0.040 |
Model D | |||
 Primary tumor (T) (III/IV vs I/II) | 1.925 | 1.237–2.995 | 0.004 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.631 | 1.060–2.509 | 0.026 |
 Distant metastasis (M) (Yes vs No) | 1.134 | 0.591–2.176 | 0.706 |
 TNM Stage (III/IV vs I/II) | 1.178 | 0.665–2.089 | 0.574 |
 Protein panela (2–3 markers high vs Othersb) | 1.269 | 0.926–1.738 | 0.138 |
Model E | |||
 Primary tumor (T) (III/IV vs I/II) | 4.006 | 2.033–7.893 | 6.0 × 10−5 |
 Lymph nodes metastasis (N) (Yes vs No) | 2.055 | 1.160–3.640 | 0.014 |
 Distant metastasis (M) (Yes vs No) | 0.781 | 0.323–1.888 | 0.583 |
 TNM Stage (III/IV vs I/II) | 0.604 | 0.262–1.389 | 0.235 |
 Combined of protein panel and CA19–9 level (2–3 markers high and CA19–9 high vs Othersc) | 1.490 | 0.922–2.406 | 0.103 |